Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma - Wikidata - awgldk - TriplyDB

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

http://www.wikidata.org/entity/Q33387009

about

Development of targeted therapies in treatment of glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.Bevacizumab and daily temozolomide for recurrent glioblastoma.Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis.Molecular targeting of glioblastoma: Drug discovery and therapies Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas Targeting the PDGF signaling pathway in tumor treatment Glial progenitors as targets for transformation in glioma.Pathway inhibition: emerging molecular targets for treating glioblastoma.Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine.The challenges and the promise of molecular targeted therapy in malignant gliomas.PDGF in gliomas: more than just a growth factor?Antiangiogenic therapy for glioma.Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas Standards of care and novel approaches in the management of glioblastoma multiforme.Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.Current concepts and management of glioblastoma.Evolution of care for patients with relapsed glioblastoma.Role of tyrosine kinase inhibitors in the management of high-grade gliomas.PDGF and PDGF receptors in glioma.Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.Angiogenesis in neurological disorders: a review.Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?Current and future directions for Phase II trials in high-grade glioma.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Molecular pathways and potential therapeutic targets in glioblastoma multiforme.Aberrant signaling pathways in glioma.Targeted therapy in gliomas.Glioblastoma multiforme: State of the art and future therapeutics.Platelet-derived growth factor in glioblastoma-driver or biomarker?Molecularly targeted therapies for recurrent glioblastoma: current and future targets.Glioblastoma targeted therapy: updated approaches from recent biological insights.

P2860

Q26778787-B23E2D89-66F6-4818-B811-88886541BA0A Q26822717-ADE12CD2-0BC7-4688-8BD0-A2CD03E4D10B Q26829873-231838DA-1EB9-467C-9C10-7EFF56739BBC Q27851556-C3689A65-E974-440E-8B3D-C35BD1386C5E Q33396384-86F972C0-CD16-4D46-BDCA-1EA6843CCD30 Q33399939-D3ADB896-2313-4EBC-A300-12F31DA6A984 Q33402044-02A1A75F-C998-4AA9-8B1A-FA4260D1D2FF Q33403967-A9BAFE01-A281-4722-88B0-9F3256CFEBAB Q33419794-8810BC1F-697A-48A5-A7F1-7B96F6D0D52D Q33687066-E6DB6960-7658-44E5-A48C-05ADC5DABB6E Q33911283-3919AF02-4862-4938-A953-AEF500176C00 Q34154786-2D8D8E8E-038C-4BB7-8284-AF24A0E9A9F7 Q34231554-543E7599-A6E1-476D-B651-EECEF51340CE Q34393461-AA13A46A-42FF-4F2C-8223-206337DC41C9 Q34735661-3BA2A49D-2596-4E5C-8689-F05A9B0C70EF Q35021359-FDB995F1-8FDC-43F1-92F8-2EAFB9CD022C Q35102675-E472CAD2-35C5-4BD8-919F-22267E246B45 Q35214534-783B3558-3704-43AA-BB36-3E04D7E01FB8 Q35920489-25AA09A2-46B9-4A51-9E6B-290575FA77C6 Q36101999-AFD7665F-44C3-4F38-B2CB-E62A5A01484F Q36544472-FFC35C54-B461-47BD-A74C-56FA70250689 Q37407817-9DF39E00-168C-4ACE-8C50-D59717E3D3B0 Q37525881-469B63D8-29CD-4007-9923-562853A137C4 Q37729676-D956B5AB-F675-4691-A086-8BBE6E5E6246 Q37904921-44BB7DC8-D39F-44B6-8AEB-506624696B68 Q37952240-E097AAB5-B8B3-43EB-B5E8-004E48DCE455 Q37952242-2503F9A6-AC3F-461F-B8D8-2B3FFD92BE28 Q38003175-A9156BA3-71C6-4839-BA6E-8D7ACB4075B7 Q38021521-7BDB9739-3161-4903-85CC-6C419725A7CB Q38034321-ADDF80CF-F3E2-45C4-8BD8-BE072388499C Q38062793-37E4EC9B-9BF1-4861-8F88-CA6A3BCE91BF Q38094808-C31E801C-FF77-4845-A3E1-AA0D558CB536 Q38108186-ACE9F301-CD8E-4F12-8248-82C149E87A36 Q38156191-DEB4C275-F164-434D-A38F-579F01CB26F1 Q38161369-6E0BED47-F86A-4736-8828-9E1FC3E39A7C Q38186656-88FD1A7B-E10F-4F6E-A012-4510214D7EB7 Q38225874-DE831AF4-7824-4C14-AE4F-25F6876BDF1A Q38262433-36A5B08A-29C8-441A-AA5D-9DF1CF138596 Q38272728-8C64075F-ACF5-4E06-A97A-A4CC1778CA85 Q38597700-1285BF8F-2829-4CFC-9440-09982CC2CD4E

P2860

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

http://www.wikidata.org/entity/Q33387009

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Multicentre phase II studies e ...... with progressive glioblastoma

@ast

Multicentre phase II studies e ...... with progressive glioblastoma

@en

type

label

Multicentre phase II studies e ...... with progressive glioblastoma

@ast

Multicentre phase II studies e ...... with progressive glioblastoma

@en

prefLabel

Multicentre phase II studies e ...... with progressive glioblastoma

@ast

Multicentre phase II studies e ...... with progressive glioblastoma

@en

P1433

Q33387009-1BA6960E-E6EA-4D59-AED9-92D305D517C2

P1476

Q33387009-CC6A621E-C0E1-4BFA-B9B3-16E1EB3D1D7D

P2093

Q33387009-0A5B1E5E-5567-4683-B962-DE731D294508

Q33387009-3B1D7EC5-BDB0-4467-BD8B-55D3C15508CA

Q33387009-5792C607-29EA-44D0-8306-4F17477F2342

Q33387009-5FE5BC5D-08DE-41FE-9D1A-70180B9FE8F6

Q33387009-6C9DE515-304F-4128-8674-D2DA38DDD290

Q33387009-6CF77959-C54F-46D5-9C6C-FED1573A16D0

Q33387009-78635DDB-1304-480D-A3C4-2F28459B4E87

Q33387009-83A266F5-6805-481C-80D9-5AD772CADE99

Q33387009-89976B6F-F36F-45F6-AE17-4F91D10218EA

Q33387009-9C2E582F-B72B-4635-8BEE-0FECFB71E876

P2860

Q33387009-00A77D7E-1909-429D-9737-82111A735382

Q33387009-00CD0735-BC50-4E45-91A7-B88288938182

Q33387009-04B0A834-2DE4-47E0-959B-27AE8E52EADA

Q33387009-0613198F-52F9-4F3E-998B-B03F075B7FF4

Q33387009-071CEC15-D885-42BA-99DC-F497A8110E64

Q33387009-07E0055D-E325-499D-AA5B-55C21086DD58

Q33387009-0F5F4CAF-B13C-443B-AC72-F27938F06B23

Q33387009-10747D7F-2064-443E-A6C8-D7A21B3C8038

Q33387009-151756A9-F875-4C39-839B-1838BA1ED133

Q33387009-168682DF-AA61-4B72-98A2-FDEF09788B8E

P2888

Q33387009-40130810-9EF4-4E1C-9190-47F576D2FCE1

P304

Q33387009-5D3F2366-679C-41CE-BB50-A4D638B70397

P31

Q33387009-2693816E-1E71-43F3-AD58-6F78B8DD6937

P356

Q33387009-AAFE3D7F-90D7-4205-B18C-1C9021FCF107

P407

Q33387009-A1F5500F-C31D-4801-9E1C-DD03725765B5

P433

Q33387009-4B0B5F05-1034-4CDA-9773-56D95C19FCFD

P478

Q33387009-0E5FB912-936A-4436-BE64-2AE0DDCFF878

P577

Q33387009-EDCA5E74-B8D9-4CB8-9ED4-BC35992D5FBA

P5875

Q33387009-4688CD2B-E768-4017-A7C8-552CF7989D16

P6179

Q33387009-2F90B47B-FCE3-4801-9C5A-300530E8C399

P698

Q33387009-617F8066-DB81-4C3C-9B74-6E4571D7E13B

P921

Q33387009-C0DE339B-11C0-4EC6-9CE9-DA7B4C302490

P932

Q33387009-0AC40B36-43FD-4284-96C8-AF04EC3BC0CC

P356

P1433

British Journal of Cancer

P1476

Multicentre phase II studies e ...... with progressive glioblastoma

@en

P2093

A Gijtenbeek

http://www.w3.org/2001/XMLSchema#string

A Weir

http://www.w3.org/2001/XMLSchema#string

D A Reardon

http://www.w3.org/2001/XMLSchema#string

E Blomquist

http://www.w3.org/2001/XMLSchema#string

G Dresemann

http://www.w3.org/2001/XMLSchema#string

H Schultz

http://www.w3.org/2001/XMLSchema#string

J Easaw

http://www.w3.org/2001/XMLSchema#string

J Raizer

http://www.w3.org/2001/XMLSchema#string

J Tonn

http://www.w3.org/2001/XMLSchema#string

L Gordower

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.

Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

P2888

P304

1995-2004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605411

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38080857

http://www.w3.org/2001/XMLSchema#string

P6179

1013740225

http://www.w3.org/2001/XMLSchema#string

P698

19904263

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2795431

http://www.w3.org/2001/XMLSchema#string